Virax Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Virax Biolabs Group
VRAX Stock  USD 0.85  0.04  4.94%   
Virax Biolabs' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Virax Biolabs' valuation are provided below:
Gross Profit
-53.1 K
Market Capitalization
3.7 M
Enterprise Value Revenue
27.2657
Revenue
6.3 K
Earnings Share
(1.62)
We have found one hundred twenty available fundamental trend indicators for Virax Biolabs Group, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Virax Biolabs Group current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Virax Biolabs Total Revenue

6,014.45

Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 463.5 K, Interest Expense of 31.4 K or Selling General Administrative of 3 M, as well as many indicators such as Price To Sales Ratio of 10.3, Ptb Ratio of 0.26 or Days Sales Outstanding of 1.9 K. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Build AI portfolio with Virax Stock
Check out the analysis of Virax Biolabs Correlation against competitors.

Virax Biolabs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4 M6.4 M1.6 M
Slightly volatile
Short and Long Term Debt Total225.4 K377 K546.9 K
Slightly volatile
Other Current Liabilities327.5 K524.6 K323.4 K
Slightly volatile
Total Current Liabilities680.7 K673.2 K1.1 M
Slightly volatile
Accounts Payable53.3 K56.1 K219.2 K
Very volatile
Cash3.2 M4.2 M1.3 M
Slightly volatile
Cash And Short Term Investments3.2 M4.2 M1.3 M
Slightly volatile
Common Stock Shares Outstanding1.8 M3.1 M1.3 M
Slightly volatile
Liabilities And Stockholders Equity4 M6.4 M1.6 M
Slightly volatile
Total Liabilities743.1 K964.8 K1.1 M
Slightly volatile
Total Current Assets3.5 M4.9 M1.4 M
Slightly volatile
Accumulated Other Comprehensive Income16 M30.3 M8.1 M
Slightly volatile
Capital Stock4.6 K4.3 K959
Slightly volatile
Short Term Debt163 K85.5 K513.7 K
Slightly volatile
Common Stock4.6 K4.3 K959
Slightly volatile
Short Term Investments48.6 K88.9 K21 K
Slightly volatile
Property Plant And Equipment Gross1.2 M2 M281.1 K
Slightly volatile
Short and Long Term Debt27.8 K29.2 K124.4 K
Slightly volatile
Intangible Assets42.6 K44.8 K153.5 K
Slightly volatile

Virax Biolabs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization463.5 K343.4 K612.5 K
Pretty Stable
Interest Expense31.4 K58.2 K67.7 K
Slightly volatile
Selling General Administrative3 M4.3 M1.6 M
Slightly volatile
Selling And Marketing Expenses29 K30.6 K16.3 K
Slightly volatile
Other Operating Expenses4 M6.2 M2 M
Slightly volatile
Research Development1.9 M1.8 M439.5 K
Slightly volatile
Total Operating Expenses3.9 M6.1 M2 M
Slightly volatile
Minority Interest5.7 K6 K23.2 K
Slightly volatile

Virax Biolabs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings29.6 K31.1 K472 K
Slightly volatile
Begin Period Cash Flow2.4 M3.6 M1 M
Slightly volatile
Total Cash From Financing Activities4.3 M5.8 M2.1 M
Slightly volatile
End Period Cash Flow3.2 M4.2 M1.3 M
Slightly volatile
Change To Netincome1.8 M1.7 M452.8 K
Slightly volatile
Issuance Of Capital Stock5.3 M5.1 M1.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.310.841.5 K
Slightly volatile
Days Sales Outstanding1.9 K1.8 K324
Slightly volatile
Average Payables112.3 K118.2 K426.1 K
Slightly volatile
Stock Based Compensation To Revenue97.8257.7016175
Slightly volatile
Capex To Depreciation1.671.758610.097
Slightly volatile
Inventory Turnover0.60.62744.5853
Slightly volatile
Days Of Inventory On Hand347582221
Slightly volatile
Payables Turnover0.691.05890.4593
Slightly volatile
Sales General And Administrative To Revenue718684171
Slightly volatile
Average Inventory16.8 K18.9 K20.6 K
Slightly volatile
Research And Ddevelopement To Revenue29528143.0465
Slightly volatile
Capex To Revenue10095.386229.6186
Slightly volatile
Cash Per Share1.721.640.8919
Slightly volatile
Days Payables Outstanding3273451.7 K
Very volatile
Income Quality0.890.75220.924
Slightly volatile
Intangibles To Total Assets0.0150.01040.0169
Slightly volatile
Current Ratio5.867.26923.1215
Slightly volatile
Receivables Turnover0.20.206591.8909
Slightly volatile
Capex Per Share0.30.520.2239
Slightly volatile
Average Receivables93.3 K124.2 K108.9 K
Very volatile
Revenue Per Share0.07780.08970.078
Slightly volatile
Interest Debt Per Share0.260.140.5219
Slightly volatile
Debt To Assets0.05570.058721.1266
Slightly volatile
Operating Cycle2.5 K2.3 K498
Slightly volatile
Days Of Payables Outstanding3273451.7 K
Very volatile
Ebt Per Ebit1.131.00671.0959
Slightly volatile
Quick Ratio5.787.12853.0811
Slightly volatile
Net Income Per E B T1.10.9771.0534
Slightly volatile
Cash Ratio5.066.28182.6947
Slightly volatile
Days Of Inventory Outstanding347582221
Slightly volatile
Days Of Sales Outstanding1.9 K1.8 K324
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.91.13231.0484
Very volatile
Fixed Asset Turnover0.00390.00410.1245
Slightly volatile
Debt Ratio0.05570.058721.1266
Slightly volatile
Price Sales Ratio10.310.841.5 K
Slightly volatile
Asset Turnover9.0E-40.0012.8452
Slightly volatile

Virax Biolabs Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 M1.7 M6.3 M
Slightly volatile

Virax Fundamental Market Drivers

Cash And Short Term Investments4.2 M

Virax Upcoming Events

27th of September 2023
Upcoming Quarterly Report
View
30th of June 2023
Next Fiscal Quarter End
View
12th of June 2024
Next Fiscal Year End
View
31st of March 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue44 K46.2 K
Total Revenue6.3 K6 K
Cost Of Revenue59.4 K48.3 K
Stock Based Compensation To Revenue 57.70  97.82 
Sales General And Administrative To Revenue 683.94  718.14 
Research And Ddevelopement To Revenue 281.12  295.18 
Capex To Revenue 95.39  100.16 
Revenue Per Share 0.09  0.08 
Ebit Per Revenue(973.45)(924.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY